Progyny's stock surged 14.30% in after-hours trading following the release of its first-quarter 2026 financial results, which significantly exceeded analyst expectations.

The company reported adjusted earnings per share of $0.50, beating the consensus estimate of $0.30 by 66.67%. Revenue for the quarter reached $328.504 million, also surpassing estimates. Notably, net income climbed 60.9% year-over-year to $24.2 million, and the company's gross margin expanded.

Adding to the positive sentiment, Progyny provided strong guidance for the second quarter and full fiscal year. Both revenue and adjusted EBITDA outlooks for Q2 and FY2026 came in above analyst estimates, signaling continued growth and operational strength to investors.